ImportantGS
Explain this story: Goldman Sachs starts MeiraGTx coverage with a USD 16 target for MeiraGTx stock
Goldman Sachs has initiated coverage of MeiraGTx (MGTX) with a Neutral rating and a USD 16.00 price target, citing regulatory uncertainty surrounding the company's lead gene therapy program. The target represents a 50.09 percent increase from its last Nasdaq price. MeiraGTx reported a significant jump in second-quarter revenue to USD 321.43 million, driven largely by licensing and collaboration income, despite negative operating cash flow.
OtherAD HOC NEWSSector and industry: FinancialsCapital MarketsTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Goldman Sachs has initiated coverage of MeiraGTx (MGTX) with a Neutral rating and a USD 16.00 price target, citing regulatory uncertainty surrounding the company's lead gene therapy program. The target represents a 50.09 percent increase from its last Nasdaq price. MeiraGTx reported a significant jump in second-quarter revenue to USD 321.43 million, driven largely by licensing and collaboration income, despite negative operating cash flow.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:GS
Published Oct 1, 2026, 20:29 ET · on this site +1h 33m